Olmesartan Medoxomilo + Hidroclorotiazida Ciclum (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomilo + Hidroclorotiazida Ciclum, is an angiotensin II receptor blocker presented as a tablet for oral use. It is used to manage high blood pressure, often in combination with a diuretic, and is prescribed for adult patients.

GNH USA supplies Olmesartan Medoxomilo + Hidroclorotiazida Ciclum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil combined with hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to lower blood pressure. - Hypertension: helps achieve target blood pressure levels in adults. - Hypertension with fluid retention: provides additional diuretic effect to reduce edema. - Resistant hypertension: used as part of a multi‑drug regimen when blood pressure remains uncontrolled.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe hypotension - Acute kidney injury - Hyperkalemia - Angio‑edema - Liver function abnormalities - Blood cell disorders such as agranulocytosis

Before initiating therapy, consider the following safety measures: - Renal function assessment: evaluate baseline creatinine and eGFR. - Electrolyte monitoring: check serum potassium and sodium levels regularly. - Pregnancy status: avoid use in confirmed or suspected pregnancy. - Concomitant NSAID use: monitor for reduced antihypertensive effect and renal impact. - Gout history: assess risk of increased uric acid levels. Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxil + hydrochlorothiazide can interact with several medicines.

Major Interactions (Avoid): - Aliskiren: may cause excessive potassium loss and renal dysfunction. - Potassium‑rich supplements: risk of hyper‑kalaemia. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): may blunt antihypertensive response and affect kidney function. - ACE inhibitors or other ARBs: additive risk of hyper‑kalaemia and renal impairment. - Antidiabetic drugs: may enhance glucose‑lowering effect, requiring dose adjustment.